At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of SGLT2 Inhibition on Aging-related Biomarkers in Older Obese Adults With Pre-diabetes
In Brief
A Phase 2 clinical trial evaluating Dapagliflozin 10 mg and Nutritional counseling for Aging. Completed, enrolled 20 participants across 2 sites.
Detailed Summary
Inhibitors of the sodium-glucose co-transporter (SGLT2) are FDA-approved for the treatment of type 2 diabetes (T2DM). Their mechanism of action involves lowering of blood glucose concentration secondary to increased glucose excretion of glucose by the kidney. These drugs also improve body weight, blood pressure, and cardiac function. Based on these pleiotropic effects, including its calorie restriction-mimetic properties, the study team hypothesize that SGLT2 drugs will impact several basic aging-related processes, including reductions in oxidative damage to DNA and proteins, advanced glycation end products (AGE) and receptor for AGE (RAGE), cellular senescence, and mitochondrial function.
Study Details
Timeline
Interventions
10 participants randomized to receive 12 weeks of daily dapagliflozin 10mg by mouth
10 participants randomized to receive 12 weeks of weekly counseling on nutrition